Spontaneous Subcapsular Hematoma from Rivaroxaban
Archives of Hematology Case Reports and Reviews · 2018
DOI: 10.17352/ahcrr.000012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Hematology Case Reports and Reviews, 2018. Verfasst von Chenna S und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Rivaroxaban was approved for stroke prevention for non-valvular atrial fibrillation in 2011, with added advantage of decreased risk of bleeding in comparison to coumadin, made it a good alternative for coumadin.
Zitieren
APA
S, C., AR, H., JB, D., VM, C., MR, F., & A, M. (2018). Spontaneous Subcapsular Hematoma from Rivaroxaban. Archives of Hematology Case Reports and Reviews. https://doi.org/10.17352/ahcrr.000012
Vancouver
S C, AR H, JB D, VM C, MR F, A M. Spontaneous Subcapsular Hematoma from Rivaroxaban. Archives of Hematology Case Reports and Reviews. 2018. doi:10.17352/ahcrr.000012
BibTeX
@article{S2018,
author = {S, Chenna and AR, Hurst and JB, Douglas and VM, Chippa and MR, Fulton and A, Moussa},
title = {Spontaneous Subcapsular Hematoma from Rivaroxaban},
journal = {Archives of Hematology Case Reports and Reviews},
year = {2018},
doi = {10.17352/ahcrr.000012}
}
EUVIMED